These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35338526)

  • 1. No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study.
    Mak JWY; Yuen NTK; Yip TCF; Lam RHM; Lam BKH; Cheng CTY; Wong GLH; Chan FKL; Ng SC
    J Gastroenterol Hepatol; 2022 Jul; 37(7):1284-1289. PubMed ID: 35338526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
    Ungaro RC; Limketkai BN; Jensen CB; Allin KH; Agrawal M; Ullman T; Colombel JF; Jess T
    Gut; 2019 Jun; 68(6):977-984. PubMed ID: 30420398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy.
    Singh S; Kim J; Zhu W; Dulai PS; Sandborn WJ; Jairath V
    Aliment Pharmacol Ther; 2020 Aug; 52(3):481-491. PubMed ID: 32573825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
    Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
    J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to 5-aminosalicylic acid maintenance treatment in young people with ulcerative colitis: a retrospective cohort study in primary care.
    Jayasooriya N; Pollok RC; Blackwell J; Bottle A; Petersen I; Creese H; Saxena S;
    Br J Gen Pract; 2023 Nov; 73(736):e850-e857. PubMed ID: 37666511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2012 Nov; 11():CD004118. PubMed ID: 23152224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
    Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
    Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD004115. PubMed ID: 20091560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
    Yen EF; Kane SV; Ladabaum U
    Am J Gastroenterol; 2008 Dec; 103(12):3094-105. PubMed ID: 18775007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
    Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.
    Madarame A; Fukuzawa M; Yamauchi Y; Kono S; Sugimoto A; Yamaguchi H; Morise T; Koyama Y; Uchida K; Suguro M; Matsumoto T; Yasuyuki K; Kawai T; Itoi T
    PLoS One; 2021; 16(8):e0255620. PubMed ID: 34347848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study.
    Yokoyama H; Takagi S; Kuriyama S; Takahashi S; Takahashi H; Iwabuchi M; Takahashi S; Kinouchi Y; Hiwatashi N; Tsuji I; Shimosegawa T
    Inflamm Bowel Dis; 2007 Sep; 13(9):1115-20. PubMed ID: 17455207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Sutherland L; Macdonald JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD000544. PubMed ID: 16625537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Sutherland L; Roth D; Beck P; May G; Makiyama K
    Cochrane Database Syst Rev; 2002; (4):CD000544. PubMed ID: 12519547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
    Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
    Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
    Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.